Zymeworks removes CFO Christopher Astle; CEO Kenneth Galbraith named interim CFO

Zymeworks Inc.

Dr. Christopher Astle removed as SVP and CFO, including principal financial and accounting officer, effective March 31, 2024.
Kenneth Galbraith, Chair, President, and CEO, appointed interim CFO, assuming principal financial and accounting duties.
Company has initiated a search for a new permanent CFO.
Mr. Galbraith's compensation arrangements remain unchanged per prior filings.
No family relationships or arrangements with other persons regarding the appointment.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Kenneth Galbraith

interim Chief Financial Officer

ZYME · Zymeworks Inc.

Effective: 2024-03-31
Filed: April 1, 2024, 7:59 PM ET

the Company’s board of directors (the “Board”) appointed Mr. Kenneth Galbraith, the Company’s current Chair of the Board, President and Chief Executive Officer, as the Company’s interim Chief Financial Officer.

Departed

Dr. Christopher Astle

Senior Vice President and Chief Financial Officer

ZYME · Zymeworks Inc.

Effective: 2024-03-31
Successor: Kenneth Galbraith
Filed: April 1, 2024, 7:59 PM ET

On March 31, 2024, Zymeworks Inc. (the “Company”) removed Dr. Christopher Astle from the positions of Senior Vice President and Chief Financial Officer, including as the Company’s principal financial officer and principal accounting officer, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kenneth Galbraith was appointed as interim Chief Financial Officer at Zymeworks Inc..

Action: appointed
Role: interim Chief Financial Officer

Exact text from the filing

the Company’s board of directors (the “Board”) appointed Mr. Kenneth Galbraith, the Company’s current Chair of the Board, President and Chief Executive Officer, as the Company’s interim Chief Financial Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Christopher Astle was removed as Senior Vice President and Chief Financial Officer at Zymeworks Inc..

Action: removed
Role: Senior Vice President and Chief Financial Officer

Exact text from the filing

On March 31, 2024, Zymeworks Inc. (the “Company”) removed Dr. Christopher Astle from the positions of Senior Vice President and Chief Financial Officer, including as the Company’s principal financial officer and principal accounting officer, effective immediately.

View on SEC.gov

Zymeworks Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-082784

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.